Victory Capital Management Inc. Has $3.51 Million Stake in Progyny, Inc. (NASDAQ:PGNY)

Victory Capital Management Inc. raised its holdings in Progyny, Inc. (NASDAQ:PGNY) by 79.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 203,277 shares of the company’s stock after buying an additional 89,941 shares during the period. Victory Capital Management Inc. owned 0.24% of Progyny worth $3,507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. increased its stake in Progyny by 47.5% in the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after buying an additional 1,183,558 shares during the last quarter. State Street Corp increased its stake in Progyny by 4.5% in the 3rd quarter. State Street Corp now owns 3,113,654 shares of the company’s stock valued at $52,185,000 after buying an additional 134,861 shares during the last quarter. Invenomic Capital Management LP acquired a new stake in Progyny in the 3rd quarter valued at $29,509,000. Fort Washington Investment Advisors Inc. OH increased its stake in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after buying an additional 695,740 shares during the last quarter. Finally, Baillie Gifford & Co. increased its stake in Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after buying an additional 456,853 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

Shares of PGNY stock opened at $20.36 on Monday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of 35.10, a PEG ratio of 2.39 and a beta of 1.41. The company has a 50-day simple moving average of $21.58 and a 200 day simple moving average of $18.61. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $38.98.

Analyst Ratings Changes

Several equities research analysts have issued reports on PGNY shares. Bank of America lifted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $24.82.

Insider Buying and Selling

In related news, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The stock was acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.